References
- Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman J M. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 373: 425–432
- Halaas J L, Boozer C, Blair‐West J, Fidahausein N, Denton D A, Friedman J M. Physiological response to long‐term peripheral and central leptin infusion in lean and obese mice. Proc Natl Acad Sci U S A 1997; 94: 8878–8883, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lembo G, Vecchione C, Fratta L, Marino G, Trimarco V, d'Amati G, Trimarco B. Leptin induces director vasodilation through distinct endothelial mechanisms. Diabetes 2000; 49: 293–297, [PUBMED], [INFOTRIEVE]
- Tartaglia L A, Dembski M, Weng X, Deng N, Culpepper J, Devos R, Richards G J, Campfield L A, Clark F T, Deeds J. Identification and expression of cloning of a leptin receptor, OB‐R. Cell 1995; 83: 1263–1271, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Montague C T, Farooqi I S, Whitehead J P, Soos M A, Rau H, Wareham N J, Sewter C P, Digby J E, Mohammed S N, Hurst J A, Cheetham C H, Earley A R, Barnett A H, Prins J B, O'Rahilly S. Congenital leptin deficiency in associated with severe early onset obesity in humans. Nature 1997; 387: 903–907, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Clement K, Vaisse C, Lahlou N, Cabrol S, Pellous V, Cassuto D, Gourmelen M, Dina C, Chambaz J, Lacorte J M, Basdevant A, Bougneres P, Lebouc Y, Froguel P, Guy‐Grand B. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998; 392: 388–401
- Considine R V, Sinha M K, Heiman M L, Kriauciunas A, Stephens T W, Nyce M R, Ohannesian J P, Marco C C, McKee L J, Bauer T L. Serum immunoreactive leptin concentrations in normal‐weight and obese humans. N Eng J Med 1996; 334: 292–295, [CROSSREF], [CSA]
- Steinberg G R, Parolin M L, Heigenhauser G JF, Dyck D J. Leptin increases FA oxidation in lean but not obese human skeletal muscle: evidence of peripheral leptin resistance. Am J Physiol Endocrinol Metab 2002; 283: E187–E192, [PUBMED], [INFOTRIEVE], [CSA]
- Wallace A M, McMahon A D, Packard C J, Kelly A, Shepherd J, Gaw A, Sattar N. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001; 104: 3052–3056, [PUBMED], [INFOTRIEVE]
- Barba G, Russo O, Siani A, Iacone R, Farinaro E, Russo P, Venezia A, Strazzullo P. Independent relationship between plasma leptin levels and high blood pressure: the Olivetti heart study. J Hypertens 2001; 19(2)S96, (Abstract)
- Correia M LG, Haynes W G, Rahmouni K, Morgan D A, Sivitz W I, Mark A L. The concept of selective leptin resistance: evidence from agouti yellow obese mice. Diabetes 2002; 51: 439–442, [PUBMED], [INFOTRIEVE]
- Mark A L, Correia M LG, Rahmouni K, Haynes W G. Selective leptin resistance: a new concept in leptin physiology with cardiovascular implications. J Hypertens 2002; 20: 1245–1250, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Haynes W G, Morgan D A, Walsh S A, Mark A L, Sivitz W L. Receptor mediated regional sympathetic nerve activation by leptin. J Clin Invest 1997; 100: 270–278, [PUBMED], [INFOTRIEVE], [CSA]
- Shek E W, Brands M W, Hall J E. Chronic leptin infusion increases arterial pressure. Hypertension 1998; 31: 409–411, [PUBMED], [INFOTRIEVE], [CSA]
- Aizawa‐Abe M, Ogawa Y, Masuzaki H, Ebinhara K, Satoh N, Iwai H, Matsuoka N, Hayashi T, Hosoda K, Inoue G, Yoshimasa Y, Nakao K. Pathophysiological role of leptin in obesity‐related hypertension. J Clin Invest 2000; 105: 1243–1252, [CSA]
- Mark A L, Shaffer R A, Correia M LG, Morgan D A, Sigmund C D, Haynes W G. Contrasting blood pressure effects of obesity in leptin‐deficient ob/ob mice and agouti yellow obese mice. J Hypertens 1999; 17: 1949–1953, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Morgan D A, Rahmouni K, Mark A L, Haynes W G. Selective leptin resistance during high fat diet in mice: preservation of sympathetic activation despite attenuation of metabolic responses. Hypertension 2001; 38: 478
- Shimomura I, Hammer R E, Ikemoto S, Brown M S, Goldstein J L. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999; 401: 73–76, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Unger R H. Leptin physiology: a second look. Regulatory Pept 2000; 92: 87–95, [CROSSREF]
- Unger R H, Orci L. Liptoxic diseases of nonadipose tissues in obesity. Int J Obes 2000; 24(Suppl 4)S28–S32
- Unger R H, Orci L. Diseases of liporegulation: new perspective on obesity and related disorders. Faseb J 2001; 15: 312–321, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Zhou Y, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L, Unger R H. Lipotoxic heart disease in obese rats: implications for human obesity. PNAS 2000; 97: 1784–1789, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Oral E A, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner A J, DePaoli A M, Reitman M L, Taylor S I, Gorden P, Garg A. Leptin‐replacement therapy for lipodystrophy. N Engl J Med 2002; 346(8)570–578, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Simha V, Szczepaniak L S, Wagner A J, DePaoli A M, Garg A. Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy. Diabetes Care 2003; 26: 30–35, [PUBMED], [INFOTRIEVE], [CSA]